Patent EP0300680A2 successfully refreshed from Google Patents.
EP0300680A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Doublestranded RNA correction of abnormalities in circulating immune complexes and monocyte function
Assignee: HEM Pharmaceuticals Corp
•
Filing: 1988-07-13
•
Granted: —
•
Expires: 2008-07-13
Abstract
Abstract The use of a double-stranded RNA for the manufacture of a medicament for treating an inflammatory disorder characterised by elevated levels of circulating immune complexes in the patient's blood.
Inventors
- 👤 William A Carter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 14:05
CPC Classifications
A; A61; A61K; A61K45/00; A61K31/00; A61K31/70; A61P; A61P29/00; A61P31/00; A61P31/12; C; C07; C07H; C07H21/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
29 words
The use of a double-stranded RNA for the manufacture of a medicament for treating an inflammatory disorder characterised by elevated levels of circulating immune complexes in the patient's blood.
Claim 2
Dependent Claim
29 words
The use of a double-stranded RNA for the manufacture of a medicament for treating an inflammatory disorder characterised by elevated levels of circulating immune complexes in the patient's blood.
Claim 3
Dependent Claim
40 words
The use of a double-stranded RNA according to claim 1 in which the inflammatory disease is caused by a microorganism, such as a virus, a bacterium or a protozoan, an auto-or self-immune process, rheumatoid arthritis, hepatitis, or systemic lupus erythematosis.
Claim 4
Dependent Claim
32 words
The use of a double-stranded RNA according to claim 2 in which the inflammatory disease is classified as a Type A, a Type B or a non A/B hepatitis virus etiologic agent.
Claim 5
Dependent Claim
18 words
The use of a double-stranded RNA for the manufacture of a medicament for restoring a patient's immunological capacity.
Claim 6
Dependent Claim
18 words
The use of a double-stranded RNA for the manufacture of a medicament for restoring a patient's immunological capacity.
Claim 7
Dependent Claim
49 words
The use of a double-stranded RNA according to claim 4 in which the mismatched double-stranded RNA is a poly I complexed with a poly C, preferably one in which the poly I complexed with the poly C is additionally complexed with an RNA-stabilising polymer such as lysine or cellulose.
Claim 8
Dependent Claim
30 words
The use of a double-stranded RNA according to any one of claims 1 to 4 in which the double-stranded RNA is polyadenylic acid complexed with polyuridylic acid , preferably mismatched.
Claim 9
Dependent Claim
56 words
The use of a double-stranded RNA according to any one of claims 1 to 4 in which the double-stranded RNA is mismatched and is a complex of a polyinosinate and a polycytidylate containing from 1 in 5 to 1 in 30 uracil or guanidine bases, and preferably the mismatched dsRNA is rI n .r(C₁₁₋₁₄,U) n .
Claim 10
Dependent Claim
34 words
The use of a double-stranded RNA according to any one of the preceding claims wherein the medicament comprises a combination of a double-stranded RNA and a lymphokine such as an interferon or an interleukin.
Claim 11
Dependent Claim
44 words
The use of a double-stranded RNA for the manufacture of a medicament for protecting thymus and bone marrow-derived cells from virus infection or spreading virus, wherein the double-stranded RNA is matched or mismatched and is capable of conferring viral resistance without adverse cellular toxicity.
Claim 12
Dependent Claim
44 words
The use of a double-stranded RNA for the manufacture of a medicament for protecting thymus and bone marrow-derived cells from virus infection or spreading virus, wherein the double-stranded RNA is matched or mismatched and is capable of conferring viral resistance without adverse cellular toxicity.
Claim 13
Dependent Claim
24 words
The use of a double-stranded RNA according to claim 9 in which the RNA is mismatched and is poly I complexed with poly C.
Claim 14
Dependent Claim
26 words
The use of a double-stranded RNA according to claim 10 in which the poly I complexed with poly C is additionally complexed with an RNA-stabilizing polymer.
Claim 15
Dependent Claim
19 words
The use of a double-stranded RNA according to claim 11 in which the stabilizing polymer is lysine or cellulose.
Claim 16
Dependent Claim
21 words
The use of a double-stranded RNA according to claim 9 in which the dsRNA is polyadenylic acid complexed with polyuridylic acid.
Claim 17
Dependent Claim
17 words
The use of a double-stranded RNA according to claim 9 in which the double-stranded RNA is mismatched.
Claim 18
Dependent Claim
37 words
The use of a double-stranded RNA according to claim 14 in which the mismatched double-stranded RNA is a complex of a polyinosinate and polycytidylate containing from 1 in 5 to 1 in 30 uracil or guanidine bases.
Claim 19
Dependent Claim
22 words
The use of a double-stranded RNA according to claim 15 in which the mismatched double-stranded RNA is rI n .r(C₁₁₋₁₄,U) n .
Claim 20
Dependent Claim
36 words
The use of a double-stranded RNA according to claim 9 in which the double-stranded RNA contains regions of bond breakage and the double-stranded RNA exhibits the favourable therapeutic ratio property of rI n .r(C₁₁₋₁₄,U) n .
Claim 21
Dependent Claim
40 words
The use of a double-stranded RNA according to claim 14 in which the medicament contains mismatched double-stranded RNA in an amount which will result in a level of from 1 to 1000 micrograms per milliliter of the patient's body fluid.
Claim 22
Independent Claim
92 words
A method of diagnosing an inflammatory disorder induced by circulating immune complexes in the patient's blood comprising assessing the circulating immune complexes in a sample of a patient's blood serum by (a) determining the level of available CR1 receptors on the red blood cells of a patient sample, (b) conducting a direct Coomb's test to determine the types of immune molecules bound to the patient's red blood cells, or (c) assessing the level of the patient's red blood cells coated with C₃ as a measure of activation of the patient's complement system.
Claim 23
Independent Claim
92 words
A method of diagnosing an inflammatory disorder induced by circulating immune complexes in the patient's blood comprising assessing the circulating immune complexes in a sample of a patient's blood serum by (a) determining the level of available CR1 receptors on the red blood cells of a patient sample, (b) conducting a direct Coomb's test to determine the types of immune molecules bound to the patient's red blood cells, or (c) assessing the level of the patient's red blood cells coated with C₃ as a measure of activation of the patient's complement system.
Claim 24
Independent Claim
74 words
A method of diagnosing and restoring a patient's immunological capacity comprising assessing the patient's immunological capacity by (a) collecting mononuclear cells from the patient, measuring the monocyte and T-lymphocyte subpopulation, and comparing the measured results to those of a known, standardized, asymptomatic population; (b) measuring the bacterial killing capacity of a patient's blood sample and comparing the measured result to those of a known, standardized, asymptomatic normal population; or (c) both (a) and (b).
Claim 25
Independent Claim
74 words
A method of diagnosing and restoring a patient's immunological capacity comprising assessing the patient's immunological capacity by (a) collecting mononuclear cells from the patient, measuring the monocyte and T-lymphocyte subpopulation, and comparing the measured results to those of a known, standardized, asymptomatic population; (b) measuring the bacterial killing capacity of a patient's blood sample and comparing the measured result to those of a known, standardized, asymptomatic normal population; or (c) both (a) and (b).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.